Hengrui Pharmaceuticals has launched a Phase III clinical trial evaluating KRAS G12D inhibitor HRS-4642 combined with gemcitabine and nab-paclitaxel versus chemotherapy alone in 588 patients with advanced or metastatic pancreatic cancer harbouring a KRAS G12D mutation. The randomised double-blind multicentre study's primary endpoints include progression-free survival (PFS) and overall survival (OS), following Phase Ib/II data showing 60% objective response rate (ORR) and 93.3% disease control rate (DCR) in thirty treatment-naive pancreatic ductal adenocarcinoma patients. The liposome-encapsulated small molecule demonstrates sustained release characteristics leveraging enhanced permeability and retention effect for tumour-targeted delivery, with a manageable safety profile and no treatment discontinuations due to adverse events.

KRAS G12D represents most common KRAS mutation variant in pancreatic cancer, occurring in approximately 45% of cases compared to G12C prevalence below 5%, creating a significant unmet need for targeted therapies. The mutation drives tumour progression through constitutive MAPK pathway activation, with current standard care yielding limited survival benefit in advanced pancreatic cancer, where five-year survival remains below 10% despite chemotherapy and emerging immunotherapy approaches.

PharmCube's NextBiopharm® database identifies 32 KRAS G12D inhibitors in clinical development, with HRS-4642 being most advanced candidate entering Phase III. Click here to request a free trial for NextBiopharm®.